The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2021 | Challenges of performing immunotherapy trials in the UK
Riyaz Shah, FRCP, PhD, Maidstone and Tunbridge Wells NHS Trust, Kent, UK, discusses the outcomes of the National Cancer Research Institute (NCRI) advanced disease subgroup meeting at BTOG 2021, outlining the challenges of undertaking clinical trials of immunotherapy for patients with advanced lung cancer in the UK. Dr Shah also talks on the REFINE study (previously called CONVOLUTE) investigating continuous versus non-continuous therapy with the anti-PD-1 monoclonal antibody pembrolizumab for patients with non-small cell lung cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
Disclosures
Riyaz Shah, FRCP, PhD, discloses links to Boehringer Ingelheim, AstraZeneca, Roche, BMS, MSD, Pfizer, Lilly, Novartis, Takeda and Bayer.
